GlassScriptPhysician profile
Dimple Amin
NPI 1982142659
$5,757.16
in general payments reported to CMS, 2019-2025
29 companies · $839 in 2025
The $839 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $863 · 2022: $1,083 · 2023: $1,221 · 2024: $1,750 · 2025: $839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,789 · Education: $21.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,789.26 |
| Education | $21.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,134.33 | 2021-2025 | Avista Mri, General - Pain Management |
| Abbott Laboratories | $1,134.08 | 2021-2025 | Proclaim, Prodigy, Eterna |
| Collegium Pharmaceutical, INC. | $1,063.76 | 2021-2025 | Xtampza, Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $800.78 | 2022-2025 | Relistor |
| Protega Pharmaceutials INC | $258.65 | 2023-2025 | Roxybond |
| Vertos Medical, INC. | $196.29 | 2024 | Mild Device Kit |
| Redhill Biopharma INC. | $169.14 | 2021 | |
| Nalu Medical, INC. | $162.85 | 2021-2024 | Nalu Neurostimulation System |
| Hikma Pharmaceuticals USA | $159.76 | 2021-2022 | |
| Nevro Corp. | $156.27 | 2022 | |
| Scilex Pharmaceuticals INC. | $89.00 | 2022-2024 | Ztlido |
| Averitas Pharma INC. | $58.47 | 2024-2025 | Qutenza |
| Almatica Pharma LLC | $55.04 | 2021-2023 | Gralise |
| Valinor Pharma, LLC | $38.64 | 2023 | Movantik |
| Amgen INC. | $35.27 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $28.52 | 2021 | |
| Bioventus LLC | $26.24 | 2023 | Gelsyn-3 |
| Avanos Medical | $23.35 | 2025 | Generator |
| Mml US, INC. | $22.32 | 2025 | Reactiv8 |
| Otto Bock Healthcare LP | $21.27 | 2024 | |
| Tonix Medicines, INC. | $17.31 | 2025 | Tonmya |
| Abbvie INC. | $17.03 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $15.58 | 2025 | |
| Novo Nordisk INC | $14.89 | 2022 | |
| Depuy Synthes Sales INC. | $14.59 | 2024 | Orthovisc, Monovisc |
| Medtronic, INC. | $14.47 | 2021 | |
| Stryker Corporation | $14.10 | 2024 | Mild Device Kit |
| Biodelivery Sciences International, INC. | $12.55 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $2.61 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dimple Amin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.